Peter MD review

Peter MD sells GLP-1 care as one line in a much wider catalog — tirzepatide and compounded semaglutide alongside TRT, sermorelin, NAD+, hair loss and ED, all on a single account. If you already want two or three of those, consolidating them under one provider is a real convenience, and Peter MD publishes a genuine price on every product page rather than gating any of them behind a quiz.

Neither GLP-1 line is a flat monthly rate, though, and that is the thing to understand before signing up. Tirzepatide is $149 for the first month and $249 a month afterwards, billed quarterly. Semaglutide splits by customer rather than by dose: $149 a month on the new-user tier and $139 on the returning-user tier, sold as compounded semaglutide with B12 rather than as a standalone product.

So the number you meet at signup is not the number you settle at. On tirzepatide the step-up is $100 a month, arriving in month two, and because billing is quarterly the second charge is the one that carries it. Read the tier you are actually on before treating any single figure as the price.

Coverage is the part most likely to catch someone out. The customer-facing pages name only Alabama and Idaho as excluded — Alaska and Hawaii too on semaglutide — but the terms attached to its affiliate program describe a materially different and longer list. There is genuinely more than one answer published, so confirm your own state at intake rather than reading either list as settled.

The rest of the catalog is priced with more discipline than the GLP-1 lines: TRT is flat at $79 a month on a twelve-month plan, and NAD+ and sermorelin are both published with a total supply cost rather than a teaser rate. Customer reviews are mixed, and no GLP-1 sold here is an FDA-approved product.